The significance of oral or locally applied Syk inhibitors for breast cancer risk is of critical concern in the context of the current development of agents targeting Syk for therapeutic treatment of allergy, asthma and autoimmune disease [39], [40]. This evidence concerns the gene SYK and asthma.